SLU-PP-332 5mg — ERR Pan-Agonist Research Compound
SLU-PP-332 is a small molecule ERR (estrogen-related receptor) pan-agonist developed by researchers at Washington University in St. Louis. It activates all three estrogen-related receptor subtypes — ERRα, ERRβ, and ERRγ — which are nuclear receptors that regulate mitochondrial biogenesis, oxidative metabolism, and energy expenditure. This 5mg vial provides research-grade SLU-PP-332 at ≥99% purity, HPLC and MS/MS verified per batch.
Research Background
SLU-PP-332 gained significant research attention following a 2023 publication in the Journal of Medicinal Chemistry (Ping et al., Washington University) demonstrating that the compound increased running endurance in mice by approximately 70% without training, alongside upregulation of mitochondrial biogenesis markers (PGC-1α, TFAM) and oxidative fiber gene expression in skeletal muscle. Additional research has explored SLU-PP-332 in cardiac metabolism and heart failure models, where ERRα plays a key regulatory role in cardiomyocyte energy substrate utilization.
For the full breakdown of SLU-PP-332’s ERR mechanism, endurance study data, comparison with AICAR, and dosage reference, see our SLU-PP-332 Research Guide.
Compound Specifications
- Format: Lyophilized powder
- Purity: ≥99% (HPLC verified)
- Quantity: 5mg per vial
- Storage: −20°C, protected from light
- Target: ERRα, ERRβ, ERRγ (pan-agonist)
Certificate of Analysis
All SLU-PP-332 vials are third-party tested by independent ISO-certified laboratories. HPLC and MS/MS validation performed per batch. COA available on request.
For research and laboratory use only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.
